Annexon, Inc. — Q2 2022 Form 10-Q Summary
Business Context and Reporting Period
Annexon is a clinical-stage biopharmaceutical company developing complement-targeted medicines for autoimmune, neurodegenerative and ophthalmic disorders. The filing covers the three and six months ended June 30, 2022, with comparative periods ended June 30, 2021. Annexon has no approved products and generated no product revenue.
- Pipeline includes five investigational candidates: ANX005, ANX007, ANX009, ANX105 and ANX1502.
- Key expected milestones included ANX005 wAIHA data in the second half of 2022, ANX009 lupus nephritis data in the second half of 2022, and several 2023 data readouts.
- During the quarter, the company reported final open-label Phase 2 Huntington’s disease data for ANX005 and planned discussions with regulators regarding a potential precision-medicine trial.
Financial Performance and Liquidity
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $29.1 million, up 18% | $56.1 million, up 24% |
| General and administrative expense | $8.3 million, up 22% | $16.7 million, up 36% |
| Total operating expenses | $37.4 million, up 19% | $72.8 million, up 27% |
| Net loss | $37.1 million, or $0.96 per share | $72.5 million, or $1.88 per share |
| Net cash used in operating activities | Not separately disclosed | $58.5 million |
- R&D spending was driven primarily by higher clinical and nonclinical outside services, which increased $4.5 million in the quarter and $8.7 million year to date, reflecting multiple ongoing clinical trials.
- G&A growth reflected higher headcount, stock-based compensation, professional services, insurance and facility costs.
- Operating and net profit margins are not meaningful because the company has no product revenue and is incurring operating losses.
- Cash and cash equivalents were $104.6 million at June 30, 2022; short-term investments were $73.0 million; combined cash and short-term investments were approximately $177.6 million.
- Total assets were $220.7 million and total liabilities were $52.7 million. The filing does not report conventional funded debt; liabilities primarily consisted of operating lease obligations and working-capital liabilities.
- Operating lease liabilities totaled $34.1 million, including $1.7 million current and $32.4 million non-current.
- Accumulated deficit was $368.8 million at June 30, 2022.
Material Changes Versus the Prior Comparable Period
- Six-month net loss increased 26%, from $57.4 million to $72.5 million.
- Six-month operating cash burn increased from $48.1 million to $58.5 million.
- R&D expense increased 24%, primarily because of expanded clinical activity; contract manufacturing expense declined as prior-year ANX005 production runs were completed.
- G&A expense increased 36%, driven by headcount-related compensation, stock-based compensation, professional services and the new Brisbane facility.
- Cash and short-term investments declined from approximately $242.7 million at December 31, 2021 to approximately $177.6 million at June 30, 2022, despite $87.9 million of net investing cash inflow largely from investment maturities.
- Stock options outstanding increased to 7.0 million from 5.7 million at year-end 2021; unvested restricted stock units increased to 285,655 from 50,000.
Guidance, Outlook, Risks and Unusual Items
- Management stated that cash on hand at June 30, 2022 was sufficient to support operations for at least 12 months following issuance of the financial statements.
- Following the quarter, the company completed a July 11, 2022 private placement generating approximately $122.7 million of net proceeds. The transaction included 9.0 million issued common shares, pre-funded warrants for up to 24.7 million shares and common warrants for up to 8.4 million shares.
- Management stated that existing resources, including the private-placement proceeds, were expected to fund operating expenses and capital expenditures into the second half of 2025. This estimate depends on assumptions that may prove inaccurate, and additional financing may be required sooner.
- Exercise of all common warrants would provide approximately $48.9 million of additional gross proceeds, but would increase potential dilution.
- The company expects R&D and G&A expenses to increase substantially as clinical programs advance, trials expand and regulatory activities continue.
- COVID-19 caused clinical-trial interruptions, clinical-site staffing shortages, slower site initiation and temporary shortages of laboratory supplies. Further effects on enrollment, timelines, suppliers and regulatory activities remain uncertain.
- Primary risks include clinical-trial failure or delay, adverse safety findings, regulatory nonapproval, dependence on third-party manufacturers and contract research organizations, intellectual-property disputes, additional financing needs and dilution, competition, data-security incidents and volatility in the common stock.
- No material legal proceedings, defaults, material indemnification claims or off-balance-sheet arrangements were reported.
- Management concluded that disclosure controls and procedures were effective as of June 30, 2022, and reported no material change in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Clinical-trial timing, enrollment, safety results and upcoming data releases for ANX005, ANX007, ANX009, ANX105 and ANX1502.
- Whether the stated funding runway into the second half of 2025 remains valid as clinical spending increases.
- The share count and potential dilution from the July 2022 private placement, pre-funded warrants, common warrants, employee awards and the unused $100 million ATM program.
- Cash burn, short-term investment maturities and the company’s ability to raise additional capital on acceptable terms.
- Regulatory feedback regarding ANX005’s development and potential registration pathway, particularly in Guillain-Barré syndrome.
- Impact of COVID-19, supply-chain constraints and third-party execution on clinical timelines and manufacturing availability.
- Validity and enforceability of the company’s owned and licensed intellectual-property portfolio.